Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, David Cameron, William Jacot et al.|New England Journal of Medicine|2022Cited by 2.5k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal CancerTakashi Kojima, Manish A. Shah, Kei Muro et al.|Journal of Clinical Oncology|2020Cited by 1.2k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upSibylle Loibl, Nadia Harbeck, Thomas Bachelot et al.|Annals of Oncology|2023Cited by 830
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the EsophagusManish A. Shah, Ken Kato, Takashi Kojima et al.|JAMA Oncology|2018Cited by 518
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialSung‐Bae Kim, L. Seigel|The Lancet Oncology|2017Cited by 474